Compare Deutsche Bank AG (DB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs TG Therapeutics Inc — how do they compare? Deutsche Bank AG trades at $38.42 (market cap $71.96B), while TG Therapeutics Inc trades at $49.53 (market cap $7.64B). The key difference: Deutsche Bank AG is far larger — about 9.4× TG Therapeutics Inc's market cap, and Deutsche Bank AG pays a 3.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DB | TGTX | |
|---|---|---|
Market Cap | $71.96B | $7.64B |
Sector | Financials | Health |
52-Week High | $40.33 | $59.06 |
52-Week Low | $28.37 | $26.94 |
Dividend Yield | 3.04% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $38.44, up 0.44% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 10.07 and P/B of 0.79, trading at a discount to book value. Recent Q2 2026 earnings missed expectations ($0.66 vs. $0.91) but the company maintains strong capital buffers and announced a new share buyback program. Revenue growth continues with 2025 revenue reaching $32.1B and net income of $6.93B, representing a 21.59% margin.
The outlook remains positive with the bank positioned as a European alternative for AI dealmaking and recent designation as China's renminbi clearing bank creating growth opportunities. However, ongoing tax investigations and mixed analyst sentiment (57.58% hold rating) present near-term risks. The combination of discounted valuation and strategic positioning offers potential upside if execution continues.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
